Methods for improving at least one neurological function in a subject that has or is suspected of having a neurologic lysosomal storage disorder using a rapamycin compound. Also provided herein are treatment of such a neurologic lysosomal storage disorder with the rapamycin compound.

The present disclosure provides for methods of treating a patient with a CYP3A4 substrate drug, wherein the patient is treated with posaconazole. In some embodiments, the patient stops posaconazole treatment, waits for at least 2 days, and then is treated with the CYP3A4 substrate drug as soon as it is safe to do so. In some embodiments, treatment with the CYP3A4 substrate drug is delayed for about 2-42 days after stopping posaconazole. In some embodiments, the patient is treated with a reduced dose of the CYP3A4 substrate drug for about 2-42 days.

The present invention relates to pharmaceutical compositions for the treatment or prevention of symptoms associated with endocrine disturbances, such as hot flashes. The pharmaceutical compositions comprise a tricyclic amino containing compound of formula (I), such as MSX-122 (also known as “Q-122”) (N,N′-(1,4-phenylenebis(methylene))bis(pyrimidin-2-amine)), and one or more pharmaceutically acceptable excipients. The pharmaceutical compositions may be given in certain doses and/or dosing regimens, preferably twice daily.

Compositions and methods are provided for treating a gut permeability-related disease or disorder comprising administering to the gastrointestinal tract of a subject in need thereof, a therapeutically effective amount of a hydrogel having an elastic modulus (G′) of at least about 500 Pa.

A method of forming a dietary supplement can include steps of creating a composition of matter comprising sakae naa and GPC; and providing the composition of matter in a liquid or solid form. Providing the composition of matter can include filling a container with the composition of matter.

This disclosure relates to dosage forms containing an enantiomerically enriched or pure bupropion such as enantiomeric excess of (S)-bupropion, enantiomerically enriched (S)-bupropion, or enantiomerically pure (S)-bupropion and methods of using these dosage forms. These dosage forms may be administered to human beings in a reduced amount as compared to the amount of racemic bupropion that would be administered in the same situation.

A method and composition for treating viral infections using a combination of naturally occurring compounds is provided. The method includes administering to a patient at risk of or diagnosed with a viral infection a composition including therapeutically effective amounts of a helicase ATPase inhibitor, a sialidase enzyme inhibitor, an ICAM-1 inhibitor and gallic acid which each also down regulate the immune response. The composition may further include a permeation enhancer.

The present disclosure provides a crystalline form of the methyl/fluoro-pyridinyl-methoxy substituted pyridinone-pyridinyl compound of the structure: XRPD, TGA, and DSC data on the crystalline form, as well as methods preparing the crystalline form, including a multi-kilo scale preparation. Also provided are pharmaceutical compositions and methods of treating p38 mediated diseases, such as lymphoma and auto-inflammatory disease, including rheumatoid arthritis. and methods of maximizing the yield thereof comprising administering of the compound. Also provided is a method of maximizing the yield of said compound via a recycling procedure.

The present disclosure provides for methods of treating a patient with a CYP3A4 substrate drug, wherein the patient is treated with posaconazole. In some embodiments, the patient stops posaconazole treatment, waits for at least 3 days, and then is treated with the CYP3A4 substrate drug as soon as it is safe to do so. In some embodiments, treatment with the CYP3A4 substrate drug is delayed for about 3-42 days after stopping posaconazole. In some embodiments, the patient is treated with a reduced dose of the CYP3A4 substrate drug for about 3-42 days.

The present invention includes a method for the treatment of age-related macular degeneration, glaucoma, or diabetic retinopathy in a human that comprises administering to the human a therapeutically effective amount of N-acetylcysteine amide (NACA) or (2R,2R′)-3,3′-disulfanediyl bis(2-acetamidopropanamide) (diNACA) sufficient to treat or reduce the symptoms of the age-related macular degeneration, glaucoma, or diabetic retinopathy.